Asston Pharma IPO Opens July 9; Issue Size ₹27 Cr

Asston Pharmaceuticals Limited is gearing up for its market debut, a prominent pharmaceutical company located in Navi Mumbai, with continuity in financial records and consistent growth trends. Asston Pharmaceuticals Limited operates in the pharmaceutical manufacturing space supplying a variety of sectors, including generating drugs, specialty pharmaceuticals, and health solutions to various sector partners across India. Asston Pharmaceuticals Limited plans to offer an IPO price of ₹123 per equity share, and a probability listing premium of 8.13%. There is an overwhelming interest in the retail and institutional realm, regarding the gmp of Asston Pharmaceuticals Limited ipo and the market is keeping a keen eye on the other pharmaceutical sector IPO listings.

IPO Dates for Asston Pharmaceuticals Limited

The Asston Pharmaceuticals Limited IPO is scheduled to open on July 9, 2025, and close on July 11, 2025. The Board of Allotment (BoA) date is expected to be announced by July 14, 2025, with listing planned for July 16, 2025.

IPO Details Summary

Investors are closely monitoring the gmp of Asston Pharmaceuticals Limited ipo, which currently shows moderate demand ahead of listing. This IPO is also part of the growing Asston Pharmaceuticals Limited IPO list on the BSE platform.

About Asston Pharmaceuticals Limited

Asston Pharmaceuticals Limited is an established pharmaceutical manufacturer based in Navi Mumbai, Maharashtra. The company operates in the pharmaceutical industry and has developed comprehensive solutions across various segments of the pharmaceutical and healthcare ecosystem, with example offerings being generic pharmaceuticals (Asston Pharmaceuticals), specialty drugs (Asston Pharmaceuticals), and healthcare solutions (Asston Pharmaceuticals Limited). As a pharmaceutical solutions company based in the commercial hub of the Mumbai region, the company is able to tap into supply chains and distribution networks, eliminating costs related to distribution and supply chain logistics and connecting it to a growing pharmaceutical manufacturing ecosystem in India. This provides Asston Pharmaceuticals Limited the ability to leverage opportunities associated with the growing pharmaceutical manufacturing ecosystem given the shift towards organized pharmaceutical services in India.

Asston Pharmaceuticals Limited has developed from a pharmaceutical manufacturing company to a comprehensive healthcare solution provider, pharmaceutical manufacturing provider, contract drug developing provider, and pharmaceutical services provider with complimentary healthcare services. The organization has developed the operational capacity in pharmaceutical production, competitive supply chain management, pharmaceutical business operational expertise, quality assurance, and customer services in the dynamic scale and competition of the pharmaceutical manufacturing landscape.The organization is utilizing all of its know-how in the pharmaceutical manufacturing and custom healthcare space to address connect the large demand for organized pharmaceutical manufacturing services.

This company is planning to raise ₹26.17 crores from the IPO in the combination of fresh issue/offer for sale. The proceeds from the IPO will position as working capital, expansion to operational capacity from increasing demand, fund the development of infrastructure, and improve operational infrastructure for all business verticals. The interest level by investors demonstrated in the Asston Pharmaceuticals Limited IPO GMP suggests positive market sentiment is supportive of investment in the organized pharmaceutical manufacturing space. The Asston Pharmaceuticals Limited ipo subscription status is expected to reflect strong investor interest when the ipo opens.

Financial Performance of Asston Pharmaceuticals Limited

The company has demonstrated steady financial performance with consistent growth across key metrics:

Performance Analysis

Asston pharmaceuticals limited has demonstrated strong growth as total assets have been steadily increasing from ₹13.69 crores in Mar-23 to ₹31.83 crores in May-25 this clearly demonstrates a growth business. Revenue has grown substantially from ₹7.19 crores in Mar-23 to ₹25.61 crores in Mar-25 which demonstrates a good level of market acceptance of their offering and clearly demonstrates a growing business. Profit after tax has improved substantially from ₹1.06 crores to ₹4.33 crores since Mar-23 which clearly demonstrates a much more efficient operation and improvement in margins . 

EBITDA has improved from ₹1.52 crores to ₹6.16 crores, clearly demonstrating excellent operational leverage in the business and certainly indicating positive signs of managing costs appropriately. Net worth has increased substantially from ₹1.99 crores in Mar-23 to ₹12.04 crores in May-25 which indicates they have a very good financial position with continued growth opportunity. The positive nature of the Asston Pharmaceuticals limited IPO GMP as of today, reflects the overall strong balance sheet performance and clearly indicates investor confidence in the company and it's positive growth trajectory.

IPO Share Reservation

The IPO share allocation follows standard SEBI guidelines for main board listings:

Strengths

• Consistent growth in assets from ₹13.69 crores to ₹31.83 crores, demonstrating consistent ability to scale the business in the pharmaceutical industry.

• Consistent growth in revenue from ₹7.19 crores to ₹25.61 crores illustrates consistent expansion of the market and a growing customer base.

• Consistent growth in profit after tax from ₹1.06 crores to ₹4.33 crores demonstrates strong operational efficiency and very good delivery.

• EBITDA rose from ₹1.52 crores to ₹6.16 crores indicating excellent cost management and operational leverage.

• Strong position with a strategic base in Navi Mumbai, excellent presence in pharmaceutical manufacturing, and the growing need from India's expanding healthcare and pharmaceutical sectors.

Risks

• The company is reliant on the pharmaceutical manufacturing sector which does make it susceptible to regulatory changes and pricing pressure.

• The regulatory compliance in the pharmaceutical manufacturing will have compliance and operational costs also has regulatory risks.

• Competition will be strong from existing local and foreign pharmaceutical manufacturing businesses which have greater access to capital and are more established in the market.

• Dependence on raw materials and complexity of the supply chain can expose it to input cost volatility and disruptions in the supply chain.

• Compared to larger listed pharmaceutical businesses small scale operations can limit a competitive edge and also may restrict growth and penetration in the market.

How to Apply for Asston Pharmaceuticals Limited IPO?

Step-by-step guide (when IPO opens):

1. Log in to your broker app (Zerodha, Angel One, Groww, etc.)
2. Navigate to the IPO section and select Asston Pharmaceuticals Limited IPO
3. Click "Apply"
4. Enter:
   • Lot size (1,000 shares minimum)
   • Bid price (₹123 or select Cut-Off)
   • Your UPI ID
5. Submit the application
6. Approve the UPI mandate in your UPI app (PhonePe, GPay, etc.)

⏰ Important: The mandate must be approved before 5 PM on the same day or before the IPO closes.

How to Check Asston Pharmaceuticals Limited IPO Allotment Status?

You can check the Asston Pharmaceuticals Limited IPO allotment status through BSE and the registrar portal once the IPO opens.

Check on BSE

• Visit the BSE official website
• Navigate to the IPO Allotment Section
• Select Asston Pharmaceuticals Limited IPO
• Enter PAN number or application number
• Submit details to get the Asston Pharmaceuticals Limited IPO BSE allotment status

Check on the Registrar Portal

• Visit Maashitla Securities Private Limited's website
• Select IPO allotment status
• Choose Asston Pharmaceuticals Limited IPO
• Enter PAN or application number
• Submit to check status

Company Address

Name: Asston Pharmaceuticals Limited
Address: 4th Floor, Office No. A-431, Balaji Bhavan, Plot No 42A, Sector-11, CBD Belapur, Navi Mumbai, Thane, Navi Mumbai, Maharashtra, 400614
Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Website: www.asstonpharmaceuticals.com

IPO Registrar

Name: Maashitla Securities Private Limited
Address: 451, Krishna Apra Business Square, Netaji Subhash Place, Pitampura, Delhi, 110034
Phone: +91 11 4512 1795 / 96
Email: ipo@maashitla.com
Website: maashitla.com/allotment-status/public-issues

Conclusion

The Asston Pharmaceuticals Limited IPO provides a good prospect for investors who are looking for exposure in India’s expanding pharmaceutical manufacturing space. The company has provided consistent financials – increasing revenue to ₹25.61 crores, steadily increasing profitability, provided compelling operational capabilities and market position. The IPO provides entry into a well-established and growing pharmaceutical sector at a share price of ₹123 with an issue size of ₹26.17 crores. The Asston Pharmaceuticals Limited IPO GMP of 8.13% suggests moderate investor interest and stable market sentiment.

The company is based in Navi Mumbai, a noted pharmaceutical hub in India and is very well positioned with exceptional connectivity to various pharmaceutical networks and commerce activities. The company's diverse pharmaceutical offerings of generic drugs, specialty pharmaceuticals and healthcare solutions provides the potential to mitigate revenue risks, along with focused opportunities for growth as they will able to draw from all three portfolio segments. The business is exposed to pharmaceutical manufacturing sector risks that can impact overall revenues and growth of its business. However, given the track record of consistent financial performance and operational excellence, Asston Pharmaceuticals Limited provides a solid option for exposure to organized pharmaceutical manufacturers.

---

Disclaimer : This analysis is prepared for educational purposes only and should not be considered as financial advice. Investors should consult their financial advisors and conduct thorough research before making investment decisions. Investments in equity markets are subject to market risks, including volatility and sector-specific challenges.

FAQs